CD133: Enhancement of Bone Healing by Local Transplantation of Peripheral Blood Cells in a Biologically Delayed Rat Osteotomy Model

Bernd Preininger1,2, Georg Duda1,3*, Hinnerk Gerigk1, Jonas Bruckner1, Agnes Ellinghaus1, F. Andrea Sass1, Carsten Perka1,2, Katharina Schmidt-Bleek1, Anke Dienelt1,3

1 Julius Wolff Institut and Center for Musculoskeletal Surgery, Charité – University Medicine Berlin, Berlin, Germany, 2 Orthopaedic Department, Center for Musculoskeletal Surgery, Charité – University Medicine Berlin, Berlin, Germany, 3 Berlin-Brandenburg Center for Regenerative Therapies, Charité – University Medicine Berlin, Berlin, Germany

Abstract

Sufficient angiogenesis is crucial during tissue regeneration and therefore also pivotal in bone defect healing. Recently, peripheral blood derived progenitor cells have been identified to have in addition to their angiogenic potential also osteogenic characteristics, leading to the hypothesis that bone regeneration could be stimulated by local administration of these cells. The aim of this study was to evaluate the angiogenic potential of locally administered progenitor cells to improve bone defect healing. Cells were separated from the peripheral blood of donor animals using the markers CD34 and CD133. Results of the in vitro experiments confirmed high angiogenic potential in the CD133(+) cell group. CD34(+) and CD133(+) cells were tested in an in vivo rat femoral defect model of delayed healing for their positive effect on the healing outcome. An increased callus formation and higher bone mineral density of callus tissue was found after the CD133(+) cell treatment compared to the group treated with CD34(+) cells and the control group without cells. Histological findings confirmed an increase in vessel formation and mineralization at day 42 in the osteotomy gap after CD133(+) cell transplantation. The higher angiogenic potential of CD133(+) cells from the in vitro experiments therefore correlates with the in vivo data. This study demonstrates the suitability of angiogenic precursors to further bone healing and gives an indication that a peripheral blood is a promising source for progenitor cells circumventing the problems associated with bone marrow extraction.

Citation: Preininger B, Duda G, Gerigk H, Bruckner J, Ellinghaus A, et al. (2013) CD133: Enhancement of Bone Healing by Local Transplantation of Peripheral Blood Cells in a Biologically Delayed Rat Osteotomy Model. PLoS ONE 8(2): e52650. doi:10.1371/journal.pone.0052650

Editor: Jan Peter Tuckermann, Leibniz Institute of Age Research – Fritz Lipmann Institute, Germany

Received May 30, 2012; Accepted November 19, 2012; Published February 14, 2013

Copyright: © 2013 Preininger et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Funding: This study was supported partially by the German Research Foundation (DFG SFB 760) and through the BMBF funded Berlin-Brandenburg Center for Regenerative Therapies. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

Competing Interests: The authors have declared that no competing interests exist.

* E-mail: georg.duda@charite.de

Introduction

Tissue regeneration closely depends on the vascular supply and deficient healing situations are frequently associated with poor blood perfusion. Such a vascular supply is crucial in the treatment of segmental bone defects or spinal fusions where poor healing outcomes as delayed unions or pseudarthrosis are frequently associated with poor angiogenesis [1,2]. It has been demonstrated in animal models that an inhibition of angiogenesis leads to a defective bone healing [3]. Thus, it can be assumed that bone healing could be improved by stimulating angiogenesis and vessel formation at the site of regeneration, providing the basic prerequisite for possible regenerative processes [4].

Mesenchymal stromal cells (MSCs) are able to differentiate into several cell types of the mesodermal lineage, such as osteoblast or chondrocytes [5]. Additionally these cells have pro-angiogenic properties and facilitate the formation of new blood vessels by secretion of factors such as VEGF-A (vascular endothelial growth factor A), b-FGF (basic fibroblast growth factor), and IGF-1 (insulin-like growth factor-1, erythropoietic factor) [6,7]. In accordance with their high regenerative capacity transplanted MSCs improve fracture healing as was shown in different animal studies [8,9]. A limitation to transfer this application into a broader setup for the therapeutic use in the clinic is the time and cost intensive isolation of MSCs by bone marrow aspiration, together with an ex vivo expansion that is necessary to reach a certain number of cells [10]. On top, the harvesting of bone marrow makes an earlier intervention prior the fracture treatment necessary that is associated with additional morbidities which ideally should be avoided. An alternative to the application of MSCs would be the use of a tissue source containing a sufficient amount of progenitor cells that can be obtained easily with low donor side morbidity but represent a similar pro-angiogenic potential as described for MSCs. Peripheral blood seems to be a good option for this strategy.

Several progenitor cell populations isolated from bone marrow that were reported to have angiogenic properties are also found circulating in the peripheral blood. CD34(+) cells are able to differentiate into endothelial cells [11] and can possibly support the formation of new blood vessels in vivo [12,13]. Other cells that were shown to support angiogenesis in experimental in vivo models are CD133(+) cells [14]. CD133(+) cells are ancestral
precursors of CD34(+) cells [15] with angiogenic potential [14,16,17].

The aim of this study was to investigate whether a sufficiently pro-angiogenic cell source could be identified from peripheral blood that would allow stimulating tissue regeneration such as in bone defect healing under impaired conditions. The regenerative potential of the cells with the high angiogenic capacity were subsequently analyzed towards their ability to enhance the healing outcome in a rat osteotomy model of impaired bone healing. The results gained from this study can serve to evaluate the local administration of angiogenic precursors cells in future treatment strategies for patients suffering from impaired bone healing situations.

Materials and Methods

In vitro characterization: flow cytometric analysis

1×10⁶ PBMCs were resuspended in FC-buffer (DPBS supplemented with 1% bovine serum albumin and 0.1% NaN₃) and stained with CD133-2-PE antibody (Miltenyi Biotec GmbH, Bergisch Gladbach, Germany), CD14-VioBlue (Miltenyi Biotec GmbH, Bergisch Gladbach, Germany) antibody and CD34-APC (Sigma-Aldrich, Munich, Germany) after blocking of unspecific binding sites by addition of FcR solution and bovine serum albumin. Stained cells were washed twice with FC-buffer, counterstained with 4',6-diamidino-2-phenylindole (DAPI) and subsequently analyzed for the occurrence of viable CD34+/CD133+ lymphocytes at a MACSQuant flow cytometer (Miltenyi Biotec GmbH, Bergisch Gladbach, Germany). For the identification of viable lymphocytes a forward/sideward scatter gate containing all lymphocytes and monocytes was set. Subsequently dead cells stained with DAPI and monocytes stained positive for CD14 were excluded via fluorescence measurements.

In vitro characterization: Tube formation Assay

Peripheral blood mononuclear cells (PBMCs) were isolated from healthy human peripheral blood derived Buffy Coats (provided from DRK, (Deutsches Rotes Kreuz) by Histopaque-1077 (Sigma-Aldrich, Munich, Germany) density gradient centrifugation. Therefore the blood was diluted with Dulbecco’s phosphate buffered saline (DPBS) at a ratio 1:1. 25 ml blood/DPBS solution were loaded onto 15 ml Histopaque, centrifuged at 400 g for 30 min without brake. The PBMCs containing layer was aspirated, transferred into a new tube and washed twice with DPBS/2mM EDTA. CD34 and CD133 positive and negative cell subpopulations were isolated from total PBMCs by immunomagnetic cell separation (MACS System; Miltenyi Biotec, Bergisch Gladbach, Germany) according to the manufacture’s instruction with the provided respective antibody. Human umbilical vein endothelial cells (HUVECs) were obtained from Lonza (Lonza Cologne AG, Cologne, Germany) and grown in Endothelial Growth Medium supplemented with growth factors (EGM and EGM-BulletKit, Lonza Cologne AG, Cologne, Germany), 100 U/mL penicillin, 100 μg/mL streptomycin and 2% fetal calf serum (FCS).

5×10⁴ HUVECs/well were plated onto 24well plates coated with 50 μl growth factor reduced Matrigel (BD Biosciences, Heidelberg, Germany). 5×10⁴ magnetically sorted cell subpopulations were seeded into cell culture inserts (1.0 μm, BD Biosciences Falcon, Bioscience, Heidelberg, Germany) and cultivated together...
Figure 3. μCT analysis – 3D reconstructions of the bone healing progress. (A) 3D reconstructions from μCT scans from one representative animal after 2, 4, and 6 weeks of the three groups are shown. In the CD133(+) group (left) mineralized tissue was formed at the endosteal as well as at the periosteal regions. After 42 days the gap had almost been bridged; a thin layer of radiolucent tissue still separated the bone ends. In the ABC group (middle) only very little callus formation was observed, appearing between the 28th and 42nd day after the osteotomy. No bridging but a cap-formation was observed, sealing the medullary canal. In the CD34(+) group (right) bone formation was further progressed than in the ABC group. After 6 weeks however, bridging did not occur and the medullary canal was closed at the proximal end. (Resolution 28 μm; scale: 2 mm). (B) Bridging score for the ABC group is lower compared with the bridging in the CD34(+) or CD133(+) group. The bridging score for the CD34(+) group showed better results than the ABC group but lesser results compared with the CD133(+). 5 areas in the osteotomy gap were investigated, 12, 3, 6, and 9 o’clock position and the centre region. The sum of bridged areas for the healing course is indicated in the table.

doi:10.1371/journal.pone.0052650.g003

Figure 4. μCT analysis – statistic evaluation of callus volume and bone mineral content. An increase of callus volume (CV, [mm³]), as well as bone mineral content (BMC, [mg]) on the basis of total mineral density of the callus was observed over time. Both parameters were significantly higher in the CD133(+) group when compared to the ABC group. Note that the differences occur not until after the 28th day and are most pronounced after the 42nd day. Comparing CV and BMC between the CD133(+) group and the CD34(+) group markedly higher values were found in the CD133(+) group. (CV: total volume, BMC: bone mineral content, wks: weeks); (CD133(+) group = grey; CD34(+) group = checkered; ABC (autologous blood clot) group = white).

doi:10.1371/journal.pone.0052650.g004
with the HUVECs for 18 hours in EGM medium without growth factors, supplemented with 100 U/ml penicillin, 100 µg/ml streptomycin and 2% FCS. Thus the two cell types shared the culture medium but were separated by the membrane of the insert. Tube formation of the HUVECs was documented after 18 hours of co-culture by bright field microscopy. The total length of tubes formed in each well was measured by ImageJ (version 1.44p; http://rsbweb.nih.gov/ij/) and correlated to the tube length formed in HUVEC co-cultures with unsorted PBMCs that served as internal control.

In vitro characterization: qPCR gene expression analysis

Total RNA was isolated from PBMCs, CD34(+)/(−) and CD133(+)/(−) cells by Trizol extraction according to the manufacturers instruction (Life Technologies GmbH, Darmstadt, Germany) [18]. The RNA concentration was determined with a Nano-Drop spectrophotometer by measuring the absorbance at 260 and 280 nm. Samples with an inappropriate 260/280 ratio were excluded from further analysis. For quantitative PCR, cDNA was synthesized from 250 ng RNA in a total volume of 25 µl with iScript reverse transcriptase as indicated by the manufacturer (Bio-Rad Laboratories GmbH, Munich, Germany). Primer sequences were generated with primer 3 (http://frodo.wi.mit.edu/) and tested for specificity with reverse ePCR (http://www.ncbi.nlm.nih.gov/projects/e-annotation/). The following primer sequences were used for analysis of the expression of basic fibroblast growth factor (b-FGF), vascular endothelial growth factor a (VEGFA), platelet derived growth factor a (PDGFa) and tata-box binding protein (Tbp): b-FGF-for 5’-aggcggagtctaaacaac-3’, b-FGF-rev 5’-ctttgtaggtggctgtct-3’, VEGFa-for 5’-ccctacgaggctcaacatg-3’, VEGFa-rev 5’-ccctcggtgccacatct-3’, PDGFa-rev 5’-caagagcgagctct-3’, PDGFa-rev 5’-ccacagctgtgcttcg-3’, Tbp-for 5’-catatatccaggggttgacgc-3’, Tbp-rev 5’-gacaaccattttcagac-3’. Using an iQ5 Cycler (Bio-Rad Laboratories GmbH, Munich, Germany) as a form giving device for the round shape of the graft a 1.5 ml Eppendorf tube (VER International GmbH, Darmstadt, Germany) was generated with primer 3 (http://frodo.wi.mit.edu/) and anti-biotin microbeads. 2 x10^5 CD34(+) and CD133(+) cells were separated by Histopaque-1077 (Sigma-Aldrich, Munich, Germany) density centrifugation and isolated subsequently following the MACS Technology protocol established by Miltenyi Biotec (Miltenyi Biotec GmbH, Bergisch Gladbach, Germany) using biotinylated CD34 (Miltenyi #130-046-702, Miltenyi Biotec, Bergisch Gladbach, Germany) or CD133 antibody (Ab16518-100 abcam lot:746560, abcam, Cambridge, UK) and anti-biotin microbeads. 2 x10^5 CD34(+) or CD133(+) cells were resuspended afterwards in 200 µl autologous whole blood. Immediately thereafter a blood clot was prepared. From each animal 200 µl of autologous peripheral blood were drawn from the right saphenic vein directly prior to surgery. Immediate coagulation was inhibited by addition of 30 µl citrate (buffered sodium citrate (equiv. to 3.2% sodium citrate), taken from BD vacutainer citrate plus plastic tubes (#363080, BD Franklin Lakes, NJ, USA). The blood was then filled into the lid of a 1.5 ml Eppendorf tube (VER International GmbH, Darmstadt, Germany) as a form giving device for the round shape of the graft to fit into the osteotomy gap. In the cell-groups CD133(+) and CD34(+) 2 x 10^5 cells were added before clotting was initiated with addition of 4 µl CaCl2 12% and 4 µl Thrombin (500 I.E./mL; Baxter Deutschland GmbH, Unterschleißheim, Germany). In the control group (ABC) the autologous clot was transplanted without addition of isolated cells.

In vivo Experimental Design: Bone defect healing

The capacity of the angiogenic potential of progenitor cells was evaluated in a small animal model for impaired bone healing. The model accounted for major risk factors such as age, female sex, and the number of parities [21–28]. In 19 female ex breeder Sprague-Dawley rats (age 12 months, weight: 412 g ±22;
In vivo Micro Computer Tomography (μCT)

After surgery bone healing was assessed by in vivo μCT at 2, 4, and 6 weeks under general anaesthesia (Medetomidin 0.3 mg/kg Domitor®, Pfizer, Karlsruhe, Germany) and Ketamin 60 mg/kg (Actavis, Langenfeld, Germany) i.p. Quantitative micro-computed tomography (vivaCT 40, Scanco, Switzerland) was applied to scan all femora and reconstruction was performed at 35 μm isotropic resolution. A volume of interest (VOI) was defined for the periosteal and endosteal callus, excluding the cortical bone and an axially 4 mm wide VOI centered to the OT-gap was applied. A global threshold for fracture callus at 233 mg HA/cm3 was set, corresponding to half of the mineralization of intact tibial cortex based on visual inspection of ten random single tomographic tibial slices from each animal. Readout parameters were bone volume (BV, mm3), total callus volume (CV, mm3), BV/TV, and tissue mineral density (TMD, mg HA/cm3). Bone mineral content (BMC) was calculated as a product of BV and BMD. 3D Pictures were reconstructed using Scanco software [30].

Bridging of the OT gap by mineralized tissue was quantified by a bridging score described earlier [21]. In brief: The OT Gap was divided into 5 regions and mineralized tissue formations bridging the gap were assessed in those 5 separate regions (12, 5, 6, 9 o’clock and centre). One blinded scorer evaluated bridging and separate region, bridging was rated 1 for bridged or 0 for non-bridged. The bridging score for every individual animal represents the sum of the scores of every region with a maximum of 5 points.

Histological Procedure and Analyses

The femurs were fixed for 2 days in normal buffered formaldehyde, dehydrated in EDTA (14 days at 37 °C), dehydrated with alcohol and xylol, and embedded in paraffin. Longitudinal serial sections (4 μm) were cut in the plane of the K-wire ducts.

Sections were stained with Movat’s Pentachrome to allow distinction between the different tissue types (bone yellow, cartilage green, connective tissue red, nuclei black) [31]. Endothelial cells formed in capillaries and vessels were identified by immune staining for faktor VIII (vWF; von Willebrandt factor). The sections were analysed for the type of tissue bridging the gap. If gap bridging was reached, mineral tissue formation was differentiated into periosteal or intercortical regions. In addition, the number of capillaries and vessels formed was counted within a determined region of interest (ROI). The ROI has been previously defined 4 mm wide centered to the middle of the OT-gap containing the entire region of callus formation captured on the histological slice.

Statistical Analyses

Mean values together with standard deviation were calculated for non-parametric data gained from the tube formation, qPCR analysis and μCT analysis. Data comparison was interpreted using the Man Whitney U Test. For statistical analysis SPSS 19.0 for Windows (SPSS Inc., Chicago, IL) was used. A p value of 0.05 or less was taken as a significant difference.

Results

Angiogenic capacity of peripheral blood derived CD34(+) and CD133(+) cells

As CD133(+) cells are described to be precursors of CD34(+) cells we first checked the analogy of these two cell populations. Indeed we found that there is a slight overlap of both cell population, but only a small number (3.34±4.52%) of CD34(+) lymphocytes express additional the marker CD133. Hence most cell express only one of the two markers CD34 or CD133 respectively and the function of both cell populations can be evaluated independently of each other.

Subsequently, we isolated CD34(+) and CD133(+) cells from PBMCs of whole blood and analyzed them for their angiogenic potential in tube formation assays. CD34(+) cells showed no significantly different impact on the tube length formed in comparison to the respective CD34(-) cell populations (0.973±0.192AU vs. 0.999±0.102AU; Fig. 1). In contrast, CD133(+) cells showed a 1.25 fold significant increase in tube length in comparison to the tube length formed in co-cultures with CD133(-) cells (1.088±0.288AU vs. 0.834±0.121AU; p = 0.0108; Fig. 1).

Growth factor expression in CD34(+) and CD133(+) cells

Beside their impact on tube formation, the expression of several pro-angiogenic growth factors was analyzed. We found that b-FGF and PDGFa were expressed 3.5fold and respectively 2.3fold more pronounced in the CD133(+) cell population in comparison to the CD34(+) cell population. However, due to the high standard deviations found in the gene expression of the different sub-populations, only the difference in the b-FGF expression in
CD133(+) cells in comparison to the CD133(−) cells was found to be significantly altered (p = 0.009) (Fig. 2A/B).

Bone formation: μCT revealed an earlier and pronounced bone formation in the CD133(+) group

To test the impact of peripheral blood derived cells on fracture repair, we analyzed the healing outcome after transplantation of CD34(+) and CD133(+) cells in a rat osteotomy model for impaired bone healing.

Bridging of the osteotomy gap occurred earlier and was more pronounced in the CD133(+) group when compared with both the CD34(+) and the ABC group (Fig. 3).

The volume of callus tissue (CV) formed in the osteotomy gap increased over time and was significantly higher in the CD133(+) group (p = 0.024) when compared with the ABC group (Fig. 4). For the CD34(+) cell group no significant increase in CV was observed when bone healing was compared to the ABC group (Fig. 4). The comparison between the CD133(+) group and the CD34(+) group revealed a better healing with higher CV values in the CD133(+) group (p = 0.061) (Fig. 4).

The BMC based on the BMD of the callus tissue formed increased over time and was significantly higher in the CD133(+) group (p = 0.022) when compared with the ABC group (Fig. 4). No significant increase in BMC was detected when comparing CD34(+) with the ABC group. The BMC was notably higher in the CD133(+) group when compared with the CD34(+) group (p = 0.051) (Fig. 4).

Both the amount and the grade of mineralization could be best increased by the addition of 2×10⁷ CD133(+) cells from the peripheral blood directly after the bone injury.

Descriptive histology confirmed a higher mineralization in the CD133(+) cell treated group

To further analyze the impact of CD133(+) cells on bone healing, we executed histological analysis of the osteotomy site from animals treated with either the blood clot or the CD133(+) cells.

In the CD133(+) group the gap region was filled with mineralized tissue 6 weeks after osteotomy in all investigated animals. Predominantly woven bone formations sending out thin spurs bridging the gap were identified (Fig. 5A).

In the ABC group the gap was mainly filled with fibrous tissue. No bridging of the osteotomy gap with cartilage or mineralized tissues was observed. Neither in the periosteal nor in the endosteal region osteogenic clusters could be seen (Fig. 5A).

Improved healing in CD133(+) group correlates with increased vessel density

In the CD133(+) group the three-fold number of capillaries and blood vessels was formed within our ROI when compared with the ABC group (74 vessels/ROI vs. 23 vessels/ROI, p<0.001). The vessels were distributed evenly within the periosteal regions and the gap region. Within the gap region vessels were mostly found at the boundary between woven bone and cartilage (Fig. 5B).

In the ABC group we found scarce numbers of capillaries and blood vessels (Fig. 5B). The vessels were distributed almost exclusively within the periosteal regions and very scarce within the gap region and the fibrous tissue.

Discussion

The presented study shows the potential of CD133(+) peripheral blood derived cells to strongly enhance angiogenesis in vitro. In correlation with these in vitro results an increased revascularization of the callus area was seen in the in vivo experiment after implementation of CD133(+) cells. This pro-angiogenic potential offers an explanation for the increased vascularisation and, possibly for the increased callus formation observed in the animal model. Thus, a local application of pro-angiogenic peripheral blood derived cells and specifically CD133(+) cells at the time of injury improved the bone healing outcome.

It is known that the revascularisation of injured tissues is a prerequisite for healing and the essential phase in the early progression of bone regeneration [32,33]. CD34(+) and CD133(+) cells have been previously described to bare angiogenic properties [12–14,16,17]. Even though CD34(+) hematopoietic stem cells are already considered as a promising candidate to further angiogenesis during bone regeneration [13], cells positive for the CD133 marker showed the highest advantage over the respective negative cells subset in our studies. CD133(+) cells have been introduced as a possible cell therapeutic for the treatment of ischemic conditions [34], but so far these cells have not been considered as a new therapy option in the context of bone injury.

By comparing both cell types in the context of bone regeneration in an model of biological impaired fracture healing only the CD133(+) cells showed a significant impact on fracture repair. That fact correlated with an increased angiogenic capacity in our in vitro analysis and an elevated gene expression of b-FGF and PDGF. The high expression of these growth factors might be responsible for the healing outcome observed, as it is known that the establishment of a non-union is correlated with a lowered serum concentration of circulating b-FGF as well as PDGF. Therefore in bone healing high concentrations of b-FGF and PDGF-AB are crucial. Beside its pro-angiogenic properties [36] b-FGF promotes also the proliferation of osteoblasts in vitro [37] and regulates bone formation in vivo [38]. PDGF is known to have an impact on angiogenesis [39] and plays a crucial role in bone regeneration [40]. Additionally, locally administered PDGF was demonstrated to improve bone healing in an rabbit osteotomy model [41]. Transplantation of the b-FGF and PDGFa expressing CD133(+) cells to the fracture gap might hence increase locally the concentration of these growth factors and lead thereby to a better revascularization and bone formation at the site of injury. Results of the in vitro study confirmed that the local application of CD133(+) cells increased vessel formation as distinctly higher numbers of vessels could be detected at the border between cartilage and woven bone in the osteotomy gap. This was coupled with a better bridging and mineralization of the femoral gap. Thus the angiogenic potential and the positive effect on bone healing of CD133(+) cells gained from peripheral blood was demonstrated. The lower regeneration capacity seen in animals treated with CD34(+) cells could be explained in this context by the lowered b-FGF and PDGF a expression that was found in comparison to CD133(+) cells.

Another important aspect of the therapeutic concept to further bone healing by CD133(+) cell transplantation leading to a better revascularisation of the injured region is the theory that osteogenic progenitors reach the fractured areas via vessels [42,43]. The endochondral ossification ultimately relies on osteoblast and their progenitors for the synthesis and mineralization of bone matrix. As a first step to regain stability in the broken bone, cartilage is formed in the osteotomy gap by chondrocytes. Later on these chondrocytes undergo hyperthrophy indicating the progression to woven bone. At the interface of hypertrophic chondrocytes and woven bone osteoblasts appear and generate bone [43]. We observed in our studies at these interface region the highest amount of new blood vessels in the CD133(+) treated.
animals. Hence it can be assumed that osteoblast reached this area by the new formed blood vessels. The initial treatment with angiogenic precursor cells therefore might not only influence the initial revascularization steps but also those occurring during the later phases of the healing cascade thus enabling a successful bone healing outcome. Besides an increased migration of cells, the forced revascularization after transplantation of CD133(+) lead also to a better nutrition and oxygen supply of local cells found in the hematoma and the fracture callus and support their proliferation and differentiation.

Angiogenic precursors, as CD133(+) cells, can be isolated from the bone marrow or from peripheral blood. The bone marrow is a rich source of progenitor cells; however the limited available amount and high donor site morbidity reported by patients contradict this approach. Peripheral blood in contrast is an easy available cell source without donor site morbidity, which makes it attractive for cell therapeutic approaches. It is known, that progenitor cells, as CD34(+) or CD133(+) are detected with lower percentages in peripheral blood when compared to bone marrow [44]. Interestingly, Eghbali-Fatourechiet al. et al. reported that the number of circulating osteogenic precursors were enriched in patients with a bone injury [45] by a mobilization from the bone marrow. Therefore the available number of CD133(+) cells in peripheral blood might also increase after fracture, which would facilitate the excitement of a suitable cell number. This would also avoid a potential necessary cell mobilization by the administration of growth factors, as this could result in negative side effects [46].

Hence, the easy availability of peripheral blood without donor site morbidity is a valuable argument for this source.

Conclusions

Locally applied precursor cell subsets gained from peripheral blood showed a potential to improve impaired bone healing in a female, aged rat osteotomy model. Computer tomography and histology revealed an improved bone healing outcome with notably more blood vessels in the perichondral region. The increase in revascularization could be one possible explanation for the enhanced healing outcome. This study demonstrates the suitability of CD133(+) cells from peripheral blood to further bone healing and gives an indication that peripheral blood is a promising source for progenitor cells circumventing the problems associated with bone marrow extraction.

Acknowledgments

No benefit of any kind has been or will be received either directly or indirectly by the authors.

Author Contributions

Conceived and designed the experiments: BP AE CP GD KSB. Performed the experiments: BP AD HG JB AE KSB FAS. Analyzed the data: BP AD HG JB KSB FAS. Contributed reagents/materials/analysis tools: BP AD HG JB KSB AE. Wrote the paper: BP AD CP GD KSB.

References

1. Hankenson KD, Duhovnitz M, Gray C, Schenker M (2011) Angiogenesis in bone regeneration. Injury 42: 556–561.
2. Giannicola G, Ferrari E, Citro G, Sacchetti B, Corsi A, et al. (2010) Graft vascularization is a critical rate-limiting step in skeletal stem-cell-mediated posteroskeletal spinal fusion. J Tissue Eng Regen Med 4: 273–283.
3. Eashuber M, Strobel C, Rauhe JS, Bergmann C, Schmidmaier G, et al. (2011) Local inhibition of angiogenesis results in an atriope non-unio in a rat osteotomy model. Eur Cell Mater 22: 1–11.
4. Carano RA, Filorolf EH (2005) Angiogenesis and bone repair. Drug Discov Today 8: 980–989.
5. Pittenger MF, Mackay AM, Beck SC, Jaiswal RK, Douglas R, et al. (1999) Multilineage potential of adult human mesenchymal stem cells. Science 284: 143–147.
6. Kimmirdl T, Stabile E, Burnett MS, Shou M, Lee CW, et al. (2006) Local delivery of marrow-derived stromal cells augments collateral perfusion through paracrine mechanisms. Circulation 109: 1543–1549.
7. Sorrell JM, Baber MA, Caplan AI (2009) Influence of adult mesenchymal stem cells on intrinsic vascular formation. Tissue Eng Part A 15: 1711–1716.
8. Arinzeh TL, Peter SJ, Archambault MP, van den Bos C, Gordon S, et al. (2003) Growth factors, as this could result in negative side effects [46].
9. Manni A, Donnelly D, Egan M, Bhandari M, (2011) The impact of implants loaded with autologous meniscal stem cells on the healing of canine segmental bone defects. J Bone Joint Surg Am 83-A: 1927–1935.
10. Bruder SP, Kraus KH, Goldberg VM, Kadylka S (1998) The impact of implants loaded with autologous meniscal stem cells on the healing of canine segmental bone defects. J Bone Joint Surg Am 80: 985–996.
11. Pittenger MF (2008) Mesenchymal stem cells from adult bone marrow. Methods Mol Biol 449: 27–44.
12. George ML, Bangalore-Praakash P, Rajorja S, Suriamo R, Shammugam A, et al. (2011) Endothelial progenitor cell biology in disease and tissue regeneration. J Hematol Oncol 4: 24.
13. Murohara T, Ikeda H, Duan J, Shintani S, Sasaki K, et al. (2000) Transplanted cord blood-derived endothelial precursor cells augment postnatal neovascularization. J Clin Invest 105: 1527–1536.
14. Arinu W, Peter SJ, Archambault MP, van den Bos C, Gordon S, et al. (2011) Allogeneic mesenchymal stem cells regenerate bone in a critical-sized canine segmental defect. J Bone Joint Surg Am 83-A: 1927–1935.
15. Summers YJ, Heyworth CM, de Wynter EA, Hart CA, Chang J, et al. (2004) Multilineage potential of adult human mesenchymal stem cells. Science 284: 1153–1156.
16. Bonanno G, Perillo A, Rutella S, De Ritis DG, Marisotti A, et al. (2004) Clinical isolation and functional characterization of cord blood CD133+ hematopoietic progenitor cells. Transfusion 44: 1087–1097.
17. Tongdrau T, Meuleman N, Delisi F, Jeunjette M, Leroy R, et al. (2005) Mesenchymal stem cells derived from CD133-positive cells in mobilized peripheral blood and cord blood: proliferation, Oct4 expression, and plasticity. Stem Cells 23: 1105–1112.
18. Chomczynski P (1995) A reagent for the single-step simultaneous isolation of RNA, DNA and proteins from cells and tissue samples. Biotechniques 15: 532–534, 536–537.
19. Dienelt A, zur Nieden NI (2011) Hyperglycemia impairs skeletogenesis from embryonic stem cells by affecting osteoblast and osteoclast differentiation. Stem Cells Dev 20: 465–474.
20. Piatt MW (2001) A new mathematical model for relative quantification in real-time RT-PCR. Nucleic Acids Res 29: e45.
21. B Preinninger HG, J Bruckner, C Perka, H Schell, K Schmidt-Stoeck-Bleck, G Duda (2012) An experimental setup to evaluate innovative therapy options for the enhancement of bone healing using BMP as a benchmark – a pilot study. eCells & Materials 23: 262–272.
22. Demir B, Haberal A, Goky P, Baskan B, Ozturkoglu E, et al. (2008) Identification of the risk factors for osteoporosis among postmenopausal women. Maturitas 60: 253–266.
23. Strube P, Sentaer U, Riha T, Kaspar K, Mueller M, et al. (2008) Influence of age and mechanical stability on bone defect healing: age reverses mechanical effects. Bone 42: 738–746.
24. Strube P, Mehta M, Barrenwalde A, Trippen J, Wilson CJ, et al. (2009) Sex-specific compromised bone healing in female rats might be associated with a decrease in mesenchymal stem cell quantity. Bone 45: 1063–1072.
25. Yamada M, Briot J, Pedrono A, Sans N, Mansut P, et al. (2007) Age- and gender-related distribution of bone tissue of osteoporotic humeral head using computed tomography. J Shoulder Elbow Surg 16: 596–602.
26. Meyer RA Jr., Desai BR, Heiner RE, Fiechtl J, Porter S, et al. (2006) Young, adult, and old rats have similar changes in mRNA expression of many skeletal genes after fracture despite delayed healing with age. J Orthop Res 24: 1933–1944.
27. Meyer RA Jr., Tsaahkis PJ, Marin DF, Banks DM, Harrow ME, et al. (2001) Age and ovariectomy impair both the normalization of mechanical properties and the accretion of mineral by the fracture callus in rats. J Orthop Res 19: 428–435.
28. David V, Lafage-Probst MH, Laroche N, Christian A, Ruegsegger P, et al. (2006) Two-week longitudinal survey of bone architecture alteration in the hindlimb-unloaded rat model of bone loss: sex differences. Am J Physiol Endocrinol Metab 290: E440–447.
29. Strube P, Mehta M, Putzner M, Matziolis G, Perka C, et al. (2008) A new device to control mechanical environment in bone defect healing in rats. J Biomech 41: 2696–2702.

30. Morgan EF, Mason ZD, Chien KB, Pfeiffer AJ, Barnes GL, et al. (2009) Micro-computed tomography assessment of fracture healing: relationships among callus structure, composition, and mechanical function. Bone 44: 335–344.

31. Olah AJ, Simon A, Gaudy M, Herrmann W, Schenk RK (1977) Differential staining of calcified tissues in plastic embedded microtome sections by a modification of Movat’s pentachrome stain. Stain Technol 52: 331–337.

32. Kolar P, Schmid-Bleek K, Schell H, Gabler T, Tosen D, et al. The Early Fracture Hematoma and Its Potential Role in Fracture Healing. Tissue Eng Part B Rev.

33. Lienau J, Schmid-Bleek K, Peters A, Haschke F, Dudis GN, et al. (2009) Differential regulation of blood vessel formation between standard and delayed bone healing. J Orthop Res 27: 1133–1140.

34. Finney MR, Fanning LR, Joseph ME, Goldberg JL, Greco NJ, et al. (2010) Umbilical cord blood-selected CD133+ cells exhibit vasculogenic functionality in vitro and in vivo. Cytotherapy 12: 67–78.

35. Weiss S, Zimmermann G, Pufé T, Varoga D, Heale P (2009) The systemic angiogenic response during bone healing. Arch Orthop Trauma Surg 129: 989–997.

36. Gospodarowicz D, Ferrari N, Schweigerer L, Neufeld G (1987) Structural characterization and biological functions of fibroblast growth factor. Endocr Rev 8: 95–114.

37. Zeng H, Du JY, Zheng QX, Duan DY, Liu Y, et al. (2008) Effects of basic fibroblast growth factor on biological characteristics of osteoblasts. Chin J Traumatol 6: 229–233.

38. Marie PJ (2012) Fibroblast growth factor signaling controlling bone formation: an update. Gene 498: 1–4.

39. Hellberg C, Ostman A, Heldin CH (2010) PDGF and vessel maturation. Recent Results Cancer Res 180: 103–114.

40. Shah P, Keppler L, Rutkowski J (2012) A review of Platelet Derived Growth Factor playing pivotal role in bone regeneration. J Oral Implantol.

41. Nash TJ, Howlett CR, Martin C, Steele J, Johnson KA, et al. (1994) Effect of platelet-derived growth factor on tibial osteotomies in rabbits. Bone 15: 203–208.

42. Schindeler A, Liu R, Little DG (2009) The contribution of different cell lineages to bone repair: exploring a role for muscle stem cells. Differentiation 77: 12–18.

43. Maes C, Kobayashi T, Selig MK, Torrekens S, Roth SI, et al. (2010) Osteoblast precursors, but not mature osteoblasts, move into developing and fractured bones along with invading blood vessels. Dev Cell 19: 329–344.

44. Chen CH, Lin W, Shye S, Kahler R, Grenier K, et al. (1994) Automated enumeration of CD34+ cells in peripheral blood and bone marrow. J Hematother 3: 3–13.

45. Eghbali-Fatourechi GZ, Lamann J, Fraser D, Nagel D, Riggs BL, et al. (2005) Circulating osteoblast-lineage cells in humans. N Engl J Med 352: 1959–1966.

46. Kavachi Y, Watanabe A, Uchida T, Yoshizawa K, Kurooka N, et al. (1996) Axote arterial thrombosis due to platelet aggregation in a patient receiving granulocyte colony-stimulating factor. Br J Haematol 94: 413–416.